T. Rowe Price Associates, Inc. recently announced the acquisition of new stake in Structure Therapeutics Inc ADR (NASDAQ:GPCR). The institutional investor has increased its shareholding in the Healthcare company by 41.74% to 2.51 million shares with purchase of 0.74 million shares. This fresh investment now brings its stake to 5.42% valued currently at $139.98 million. In addition, Driehaus Capital Management LLC raised its holdings by 1.25 million to 2.39 million shares. And Janus Henderson Investors US LLC has lifted its position by 20,972.28% or 1.93 million shares – to 1.94 million shares.
Currently, there are 36.59M common shares owned by the public and among those 33.10M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Structure Therapeutics Inc ADR are T Rowe Price New Horizons Fund, Federated Hermes Kaufmann Small C, and Federated Hermes Kaufmann Fund. T Rowe Price New Horizons Fund owns 0.71 million shares of the company’s stock, all valued at over $39.5 million. The company sold 300.0 shares recently to bring their total holdings to about 1.53% of the shares outstanding. Federated Hermes Kaufmann Small C bought 87500.0 shares to see its total holdings expand to 0.59 million shares valued at over $32.72 million and representing 1.27% of the shares outstanding. Federated Hermes Kaufmann Fund now owns shares totaling to 1.08% of the shares outstanding.
However, the script later moved the day high at 40.30, down -42.82%. The company’s stock has a 5-day price change of -42.45% and -3.89% over the past three months. It has a 12-month low price of $20.80 and touched a high of $75.02 over the same period. GPCR has an average intraday trading volume of 960.83K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -40.47%, -44.78%, and -10.37% respectively.
Institutional ownership of Structure Therapeutics Inc ADR (NASDAQ: GPCR) shares accounts for 81.41% of the company’s 36.59M shares outstanding. Mutual fund holders own 21.37%, while other institutional holders and individual stakeholders account for 41.65% and — respectively.
It has a market capitalization of $1.21B. The earnings-per-share (ttm) stands at -$2.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.05% over the week and 9.34% over the month.
Analysts forecast that Structure Therapeutics Inc ADR (GPCR) will achieve an EPS of -$0.22 for the current quarter, -$0.24 for the next quarter and -$0.98 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.23 while analysts give the company a high EPS estimate of -$0.21. Comparatively, EPS for the current quarter was -$1.14 a year ago. Earnings per share for the fiscal year are expected to increase by 83.56%, and -14.74% over the next financial year.
Looking at the support for the GPCR, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on October 19, 2023, with the firm’s price target at $90.
